B · Normal
On October 27, AstraZeneca (AZN)’s ENHERTU was approved in the European Union for the treatment of HER2-positive early breast cancer.
Related telegraphs
October 27th: GlaxoSmithKline expects to nearly double the number of cancer drug
10-27 15:41
On October 27, the CEO of Novartis said that sales of ribrutinib are still likel
10-27 14:59
[Sino Biopharmaceuticals: TQ-A3334 and TQA3605 were included in the breakthrough
10-27 08:31
[Hepatitis B cure drugs are expected to be approved for marketing in China by th
10-23 11:18
[The concepts of innovative drugs and CRO fluctuated and fell, and Hongbo Pharma
10-23 09:58
[The concept of innovative drugs surged, with Laimei Pharmaceutical and Xidian P
10-21 09:34
Comments